Together, these data indicate that the classical ACE-1/Ang-II pathway is dysregulated in AD and that restoring the balance of downstream ACE-1 (overactive) and ACE-2 (underactive), or the balance between AGTR1 and AGTR2 expression (16) within the brain, are potential targets for therapeutic intervention in AD (17). The gene discussed is ACE2; the disease is Alzheimer disease.